rilpivirine + tenofovir + emtricitabine
||rilpivirine + tenofovir + emtricitabine
|Also known as
||Complera in the United States
||Fixed Dose Combinations
||Available in doses suitable for children and/or young people.
|Availability in Australia
Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers since 2012
This drug may be available through clinical trials in Australia.You may be able to import this drug from overseas for your personal use.
||25 mg rilpivirine; 300mg tenofovir; 200mg emtricitabine
Like most anti-HIV drugs, rilpivirine + tenofovir + emtricitabine must be taken in combination with other drugs to be completely effective. Commonly, rilpivirine + tenofovir + emtricitabine is combined with one other nucleoside (NRTI) drug and either a protease inhibitor or non-nucleoside, although other combinations are sometimes used. Your doctor will advise you on the right combination of drugs to suit your circumstances.
One tablet once a day
Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.
With or without food
rilpivirine + tenofovir + emtricitabine must be taken with a high-fat meal
All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.
- Common side effects may include rash, insomnia, headaches.
- Less common side effects may include depression, mood swings.
It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.
Interactions with other drugs
Nephrotoxic agents. Medicinal products that decrease or compete for renal clearance or compete with active tubular secretion. Didanosine (closely monitor for didanosine-associated adverse events). Atazanavir, atazanavir/ritonavir. QT prolonging drugs. Drugs inducing or Inhibiting CYP3A enzymes (see CONTRAINDICATIONS). Drugs Increasing Gastric pH (including proton pump inhibitors) (see CONTRAINDICATIONS). Potential interactions to take into consideration (no EVIPLERA dose adjustment required): darunavir/ritonavir, lopinavir/ritonavir, azole antifungal agents (ketoconazole), methadone (clinical monitoring and potential adjustment of methadone maintenance therapy). Meal planning required: famotidine and H2receptor antagonists.